Trial · NCT03467152
Results by group130
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 130
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of Treatment | Placebo | Baseline | 13.9 | Standard Deviation 5.40 | score on a scale |
| Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of Treatment | Irsenontrine 50 mg | Baseline | 13.8 | Standard Deviation 5.18 | score on a scale |
| Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of Treatment | Placebo | Change at Week 12 | -0.6 | Standard Deviation 2.63 | score on a scale |
| Change From Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Week 12 of Treatment | Irsenontrine 50 mg | Change at Week 12 | -0.4 | Standard Deviation 3.41 | score on a scale |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | Marked improvement | 0 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Marked improvement | 0 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | Moderate improvement | 5 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Moderate improvement | 3 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | Minimal improvement | 13 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Minimal improvement | 18 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | No change | 32 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | No change | 32 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | Minimal worsening | 30 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Minimal worsening | 28 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | Moderate worsening | 6 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Moderate worsening | 8 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Placebo | Marked worsening | 0 | Participants | |
| Number of Participants Based on Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-Plus) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Marked worsening | 0 | Participants | |
| Clinician's Global Impression of Change - In Dementia With Lewy Bodies (CGIC-DLB) Scale at Week 12 of Treatment | Placebo | Marked improvement | 1 | Participants | |
| Clinician's Global Impression of Change - In Dementia With Lewy Bodies (CGIC-DLB) Scale at Week 12 of Treatment | Irsenontrine 50 mg | Marked improvement | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03467152/results